

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifiers

Product name : Sitravatinib

Product Number : 10-4826

Brand : Focus Biomolecules CAS-No. : 1123837-84-2

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting, Pa 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # CHEMTREC within USA/Canada 1-800- 424-9300

CHEMTREC outside USA/Canada 1-703-527-3887

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, Oral (Category 4), H302

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram

!>

Signal word Warning

Hazard statement(s)

H302 Harmful if swallowed.

Precautionary statement(s)

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel

Sitravatinib Page 1 of 8

P501 Dispose of contents/ container to an

Dispose of contents/ container to an approved waste disposal

plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

SECTION 3: Composition/information on ingredients

3.1 Substances

Synonyms : 1-N'-[3-Fluoro-4-[2-[5-[-[(2-methoxyethylamino)methyl]

oyridin -2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamode; MGCD516

Formula : C33H29N5O4S Molecular weight : 629.68 g/mol CAS-No. : 1123837-84-2

Component	Classification	Concentration
Sitravatinib		
	Acute Tox. 4; H302	<= 100 %

For the full text of the H-Statements mentioned in this Section, see Section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed No data available

Sitravatinib Page 2 of 8

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, Nitrogen oxides (NOx), Sulfur oxides

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Avoid breathing dust. For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs.

Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20°C

Keep in a dry place.

Storage class (TRGS 510): 13: Non Combustible Solids

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

Sitravatinib Page 3 of 8

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Do not let product enter drains.

SECTION 9: Physical and chemical properties

a) Appearance

9.1 Information on basic physical and chemical properties

Form: powder

u)	Appearance	romm. powaci
b)	Odor	No data available
c)	Odor Threshold	No data available
d)	pH	No data available
e)	Melting point/freezing point	No data available
f)	Initial boiling point and boiling range	No data available
g)	Flash point	No data available
h)	Evaporation rate	No data available
i)	Flammability (solid,	No data available

Sitravatinib Page 4 of 8

gas)

j) Upper/lower flammability or explosive limits
k) Vapor pressure No data available
l) Vapor density No data available
m) Relative density No data available
n) Water solubility No data available

o) Partition coefficient:

No data available

n-octanol/water

No data available

p) Auto-ignition temperature

q) Decomposition temperature

No data available

r) Viscosity No data availables) Explosive properties No data availablet) Oxidizing properties No data available

9.2 Other safety information

No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Sulfur oxides

Other decomposition products - No data available

In the event of fire: see section 5

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

No data available

Sitravatinib Page 5 of 8

Inhalation: No data available Dermal: No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is

identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

Reproductive toxicity

No data available

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: Not available

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

Sitravatinib Page 6 of 8

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

Contaminated packaging

Dispose of as unused product.

SECTION 14: Transport information

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

SECTION 15: Regulatory information

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Sitravatinib CAS-No. Revision Date 112837-84-2

New Jersey Right To Know Components

Sitravatinib Page 7 of 8

Sitravatinib CAS-No. Revision Date 1123837-84-2

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

SECTION 16: Other information

Further information

Copyright 2021 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 03/08/2021

Sitravatinib Page 8 of 8